Soleno Therapeutics Inc (NASDAQ: SLNO)’s stock price has plunge by -2.16relation to previous closing price of 50.05. Nevertheless, the company has seen a 0.39% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-26 that First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26 th, at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS).
Is It Worth Investing in Soleno Therapeutics Inc (NASDAQ: SLNO) Right Now?
The 36-month beta value for SLNO is at -2.12. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLNO is 33.47M, and currently, shorts hold a 14.90% of that float. The average trading volume for SLNO on March 27, 2025 was 542.31K shares.
SLNO’s Market Performance
The stock of Soleno Therapeutics Inc (SLNO) has seen a 0.39% increase in the past week, with a 9.16% rise in the past month, and a 8.39% gain in the past quarter. The volatility ratio for the week is 4.41%, and the volatility levels for the past 30 days are at 5.44% for SLNO. The simple moving average for the last 20 days is 3.37% for SLNO stock, with a simple moving average of 0.65% for the last 200 days.
Analysts’ Opinion of SLNO
Many brokerage firms have already submitted their reports for SLNO stocks, with Stifel repeating the rating for SLNO by listing it as a “Buy.” The predicted price for SLNO in the upcoming period, according to Stifel is $74 based on the research report published on March 05, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see SLNO reach a price target of $74. The rating they have provided for SLNO stocks is “Buy” according to the report published on December 02nd, 2024.
Robert W. Baird gave a rating of “Outperform” to SLNO, setting the target price at $72 in the report published on December 02nd of the previous year.
SLNO Trading at 2.20% from the 50-Day Moving Average
After a stumble in the market that brought SLNO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.62% of loss for the given period.
Volatility was left at 5.44%, however, over the last 30 days, the volatility rate increased by 4.41%, as shares surge +8.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.73% upper at present.
During the last 5 trading sessions, SLNO rose by +0.39%, which changed the moving average for the period of 200-days by +9.70% in comparison to the 20-day moving average, which settled at $47.37. In addition, Soleno Therapeutics Inc saw 8.94% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SLNO starting from Yen Kristen, who sale 2,520 shares at the price of $45.41 back on Jan 02 ’25. After this action, Yen Kristen now owns 78,945 shares of Soleno Therapeutics Inc, valued at $114,431 using the latest closing price.
Yen Kristen, the of Soleno Therapeutics Inc, sale 2,340 shares at $46.18 during a trade that took place back on Jan 03 ’25, which means that Yen Kristen is holding 76,605 shares at $108,053 based on the most recent closing price.
Stock Fundamentals for SLNO
The total capital return value is set at -0.59. Equity return is now at value -87.35, with -68.74 for asset returns.
Based on Soleno Therapeutics Inc (SLNO), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -1.31. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -796.35.
The liquidity ratio also appears to be rather interesting for investors as it stands at 15.68.
Conclusion
In conclusion, Soleno Therapeutics Inc (SLNO) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
